Phaseline

Companies › Theriva Biologics

Theriva Biologics : clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SYN-004
Recombinant class-A beta-lactamase that hydrolyzes beta-lactam rings of susceptible antibi
–Phase 1Acute Graft-Versus-Host Reaction Following Bone Marrow TransplantSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04692181SYN-004Phase 1Acute Graft-Versus-Host Reaction Following Bone Marrow TransplantImmunologySep 2029

From the company's SEC filings

Cash of $11m on 2026-06-30; operating cash outflow about $11m a year; runway about 12 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.